Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

    ... Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy -resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to ...

    Research Article last updated 01/09/2012 - 2:17pm.

  2. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... multiple myeloma (MM) and myelodysplastic syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response ... on treatment and achieve optimal efficacy, is discussed. Secondary primary malignancies in MM and progression to acute myeloid leukemia ...

    Research Article last updated 11/16/2011 - 2:10pm.

  3. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... 30% bone marrow blasts . METHODS: This secondary analysis of the AZA-001 phase 3 study evaluated the time to first ... may enhance clinical benefit in patients with higher-risk MDS. Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Myelodysplastic syndromes: an update on molecular pathology.

    ... The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterised by impaired ... of involved loci is increased in high-risk disease and secondary leukaemias. A better understanding of the pathogenesis of MDS can ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Risk of developing MDS and AML after radiation treatment for breast cancer

    ... to access the full report. Abstract # 6560 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) ...

    Research Review last updated 05/02/2016 - 9:32am.

  7. MEDALIST Trial

    ... very low, low, or intermediate Myelodysplastic syndrome (MDS) with ring sideroblasts (≥ 15%) who require Red blood cell (RBC) ... MDS associated with del 5q cytogenetic abnormality Secondary MDS , ie, MDS that is known to have arisen as the result of ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  8. Youmna Kfoury, PhD

    ... Myelodysplastic Syndromes (MDS) are a group of diverse and incurable pre-leukemic disorders. Even though a ... Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857. Sacchetti, B., Funari, A., ...

    Grant Recipient last updated 12/15/2016 - 12:56pm.

  9. David Araten, MD

    ... Secondary mutations and thrombosis in PNH ... with the generous support of the Aplastic Anemia and MDS International Foundation, to test a larger number of patients for mutations ...

    Grant Recipient last updated 11/30/2016 - 10:51am.

  10. Hematopoietic Stem Cell Transplantation in Aplastic Anemia

    ... risk of developing myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).  Many patients treated with ... Also, remember that if aplastic anemia develops into MDS or AML, then outcomes aren’t as good. The survival is lower due to ... What is not known is if eltrombopag affects the risk of secondary events such as relapse and clonal progression, especially in the ...

    Interview last updated 11/28/2016 - 2:58pm.